HLS Therapeutics (TSE:HLS)‘s stock had its “outperform” rating reiterated by Raymond James in a report issued on Tuesday, Stock Target Advisor reports. They currently have a C$28.00 target price on the stock. Raymond James’ price target suggests a potential upside of 49.02% from the company’s current price.
Separately, Canaccord Genuity upped their price target on HLS Therapeutics to C$33.00 and gave the stock a “strong-buy” rating in a research note on Friday, March 19th.
Shares of HLS Therapeutics stock traded down C$0.21 on Tuesday, hitting C$18.79. 32,300 shares of the company’s stock traded hands, compared to its average volume of 35,346. HLS Therapeutics has a one year low of C$13.35 and a one year high of C$21.76. The company has a debt-to-equity ratio of 66.02, a current ratio of 1.29 and a quick ratio of 0.93. The company has a fifty day moving average of C$19.74 and a two-hundred day moving average of C$17.72. The company has a market capitalization of C$597.94 million and a price-to-earnings ratio of -31.58.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia.
Featured Article: Sell-Side Analysts
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.